Nagel R L
Division of Hematology, Albert Einstein College of Medicine/Montefiore Medical Center, The Bronx, New York 10461, USA.
Curr Opin Hematol. 2001 Mar;8(2):105-10. doi: 10.1097/00062752-200103000-00008.
Sickle cell anemia is the first monogenic disease ever described, and it became the paradigm for a disease traceable to a single mutation in a single gene. Pauling's concept of "molecular disease," based on this discovery, opened a new chapter in the history of medicine. Nevertheless, at the phenotypic level, sickle cell anemia is not a monogenic disease; it is a multigenic disease. The latter is the product of pleiotropic genes (involved in secondary pathophysiologic events) and epistatic genes (same gene but with significant pathophysiologic consequences among individual=polymorphism). These secondary events are an important part of the phenotype and explain the intense interindividual differences in the severity of the disease, in spite of all the patients having the same sickle globin gene in the homozygote form. In the last decade a number of epistatic genes and pleiotropic genes have been defined, and many others are potential candidates. CHIP technology and high-throughput sequencing promise to accelerate our full multigenic understanding of this disease, contributing to a more individualized concept of disease in conjunction as we enter the new millennium.
镰状细胞贫血是有史以来描述的第一种单基因疾病,它成为了一种可追溯到单个基因单一突变的疾病范例。基于这一发现,鲍林的“分子疾病”概念开启了医学史上的新篇章。然而,在表型水平上,镰状细胞贫血并非单基因疾病;它是一种多基因疾病。后者是多效基因(参与继发性病理生理事件)和上位基因(相同基因但在个体间存在显著病理生理后果=多态性)的产物。这些继发性事件是表型的重要组成部分,尽管所有患者均为纯合子形式的相同镰状球蛋白基因,但它们解释了疾病严重程度上个体间的巨大差异。在过去十年中,已经确定了一些上位基因和多效基因,还有许多其他潜在候选基因。芯片技术和高通量测序有望加速我们对这种疾病的全面多基因理解,随着我们进入新千年,有助于形成更个性化的疾病概念。